A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Inclusion Criteria

• •Pathological diagnosis of PMBCL , and did not receive any previous treatment for PMBCL ;
• •Predicted survival time ≥ 6 months ;
• •18-75 years ;
• •IPI score 0-3；
• •ECOG performance status 0-2 ;
• •Clinicians judge that the patient is suitable for the treatment of primary mediastinal large B-cell lymphoma ;
• •After the patient was enrolled in the trial, other drugs that may have therapeutic effects on primary mediastinal large B-cell lymphoma were not acceptable ;
• •WBC ≥ 3 × 109 / L, NE ≥ 1.5 × 109 / L, PLT ≥ 100 × 109 / L ;
• •Serum creatinine ≤ 1.5mg / dL, creatinine clearance rate ≥ 50mL / min ;
• •ALT, AST ≤ 3 × ULN ( normal upper limit ) ; total bilirubin ≤ 2 × ULN ;
• •Sign the informed consent.